Shares of Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) were up 3.8% on Wednesday . The stock traded as high as $0.41 and last traded at $0.41. Approximately 11,166 shares traded hands during trading, a decline of 46% from the average daily volume of 20,761 shares. The stock had previously closed at $0.39.
Panbela Therapeutics Price Performance
The stock’s fifty day simple moving average is $0.37 and its two-hundred day simple moving average is $0.35. The company has a market capitalization of $1.62 million, a price-to-earnings ratio of 0.00 and a beta of 1.40.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Recommended Stories
- Five stocks we like better than Panbela Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What is the FTSE 100 index?
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- How to Use the MarketBeat Dividend Calculator
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
